Triplet versus doublet combination regimens for the treatment of relapsed or refractory multiple myeloma: A meta-analysis of phase III randomized controlled trials
| Autor: | Fang Zheng, Hehe Guo, Yichen Liu, Suwan Wu, Yanjuan Liu, Zhiqiang Sun |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Refractory law Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans 030212 general & internal medicine Prospective Studies Adverse effect Multiple myeloma Randomized Controlled Trials as Topic business.industry Hazard ratio Hematology medicine.disease Thrombocytopenia Confidence interval Surgery Clinical Trials Phase III as Topic 030220 oncology & carcinogenesis Relative risk Meta-analysis business Multiple Myeloma Publication Bias |
| Zdroj: | Critical reviews in oncology/hematology. 113 |
| ISSN: | 1879-0461 |
| Popis: | During the past decades, several prospective trials had been conducted to assess the efficacy and toxicities of triplet versus doublet combination regimens for the treatment of relapsed or refractory multiple myeloma (RRMM), but the results were controversial. We thus performed a systematic literature search to identify relevant trials. Summary hazard ratios (HRs), relative risks (RRs), and 95% confidence intervals (95%CIs) were calculated. A total of 3197 RRMM patients were included for analysis. The pooled results demonstrated that triplet combination therapies significantly improve OS (HR 0.83, 95%CI: 0.71-0.94, p=0.004) and PFS (HR 0.68, 95%CI: 0.62-0.74, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect